Member of executive committee charged with leading corporate strategy, commercial development, and competitive intelligence at late clinical stage allogeneic cell therapy startup.

Led organizational long-range planning process, which influenced the following initiatives:- Valuation: Partnered with finance to value enterprise. - Investment: Helped prioritize portfolio programs for ~$74M annual operating budget.- Financing: Crafted pitch for $115M Series B and wrote S-1 business section for $150M IPO.- Corporate Development: Led portfolio expansion team to evaluate and execute on new opportunities.- Competitive Intelligence: Established function and hired and managed PhD-level senior manager.

Commercial lead for all clinical (P3 and P2) and preclinical programs of novel immune tolerance cell therapy FCR001 in solid organ transplant and autoimmune disease indications.

Recruited by CEO as second commercial employee to support launch of startup’s first product, Tymlos, for osteoporosis and advance/partner life cycle management, oncology, and endocrine programs.• Managed a team of 12 senior consultants and two FTEs to design and implement US commercial organization.- Developed Launch Forecast: Informed commercial footprint needed, resulting in hiring ~300 FTEs.- Led Market Research: Supported multiple award-winning consumer and HCP marketing campaigns.- Co-built and Led Commercial Analytics Infrastructure: Acquired and analyzed market data and helped enable Tymlos to achieve over 30% NBRx share in its class within its first year on US market.• In partnership with R&D, BD, and executive leadership, led commercial pitch to out-license breast cancer drug, Elacestrant, now approved as Orserdu, for $30M upfront and $320M in milestones plus royalties.

Led international teams of PhD, MD, and MBA-level life sciences consultants on dozens of BD, commercial, and financing strategy engagements for global biopharmaceutical clients.

Led strategic initiatives to identify, evaluate, and in-license new product or adjacent franchise opportunities.• Developed and secured buy-in for process of identifying and triaging opportunities with strategic fit.• One of 100 employees selected globally to participate in corporate strategy refresh commissioned by newly hired CEO. Member of team charged with defining buy-side BD and M&A priorities.- Headed orphan products strategy: culminated in recommendations that subsequently informed several multi-billion-dollar deals.- Led commercial evaluation for two proposed transactions of over $500M that progressed to full diligence.• Selected by commercial leadership as part of core team to design global analytics and insights organization.

Headed department tasked with leading commercial development and partnering strategy for portfolio of biologics for hematology, oncology, neuromuscular, and bone indications

• Market development lead for acute CV and hemophilia aptamer products.• Contributed to valuation and negotiation of $315M hemophilia asset sale, and inflammation and oncology alliances valued at $1.4B and $611M respectively.

• Co-led commercial strategy, market research and valuation for pipeline products, notably TPI-926, the company’s lead asset for Parkinson’s Disease, and transdermal candidates in oncology and neurology• Worked with BD to inform valuation of $230M acquisition by J&J

• As part of brand team, led primary and secondary market research, forecasting, and sales analytics for INTEGRILIN, the leading cardiovascular product in its class for acute coronary syndromes. • Supported market expansion initiatives: re-positioning; re-branding; launch of a new sales force and optimization of existing sales force; and valuation of ex-US partnership.

Commercial lead on project core teams for biologics and gene therapy development programs in the therapeutic areas of oncology, neurology, and autoimmune diseases